OraSure Technologies competitors

Patrick Miles is a Chairman & CEO at Aphatec Spine and is based in San Diego, California. She has experience at Smith & Nephew and has worked as Chairman at ALPHATEC HOLDINGS, INC.; Exec VP:Product Mktg & Dev at NUVASIVE INC; and Board Member at NUVASIVE INC. Patrick studied at MERCER UNIVERSITY between 1984 and 1988.

Michael A. Mussallem, age 56, has been chairman and CEO of Edwards Lifesciences, Inc. since 2000. Prior to 2000, Mussallem held a variety of positions with increasing responsibility in engineering, product development and senior management at Baxter International Inc., including Group Vice President of its CardioVascular business from 1994 to 2000 and Group Vice President of the Biopharmaceutical business from 1998 to 2000. From 1996 until 1998, he was the Chairman of Baxter's Asia Board overseeing Baxter's operations throughout Asia. Mr. Mussallem is chairman of the board of directors of the Advanced Medical Technology Association (AdvaMed), and serves as a member of the board for Advanced Medical Optics. He is also on the boards and executive committees of the California Healthcare Institute and OCTANe, and is a trustee of the University of California, Irvine Foundation. He received a bachelor's degree in chemical engineering in 1974 and an honorary doctorate in 1999 from the Rose-Hulman Institute of Technology in Indiana.

John Onopchenko is a Board Member at Synecor, Board Member at Endologix Inc, and Chief Executive Officer at Endologix Inc. He has worked as Chief Operating Officer at VOLCANO CO., LTD.; Chief Operating Officer at Endologix Inc; and Exec VP:Strategy at VOLCANO CO., LTD.. John works or has worked as VP:Venture Investments at Johnson & Johnson Innovation - Jjdc Inc, Managing Director/Gen Partner at Synergy Life Sciences Partners, and MEMBER at FINRA. He studied at University of Chicago Booth School of Business and Ursinus College.

A Strategic and Operational CFO with broad & deep geographic and business experience in Pharmaceutical, Biotech, Medical Device & Consumer Goods leading international markets worldwide in Financial operations, General Management, Information Technology, Procurement & Facilities. A strategic thinker partnering with leadership to develop long-range plans and deliver business & financial results through fact-based decision support, developing diverse cross-functional talent and implementing comprehensive metrics. Identify and sponsor change through P&L efficiencies, improved cash flow and new business models, fueling profit growth and margin expansion. Appling this approach to lead “beyond the numbers” with broad business acumen to impact the business.Recognized as a thought leader and business partner with a hands-on approach going beyond the financial leader role, a strong communicator who sorts through complexity and asks the right questions, willing to challenge the status quo & lead transformational change. Develop global finance organizations, placing leaders beyond the finance function.Experienced Management Board member of various sized healthcare, life science and consumer goods companies from start-up to multi-billion dollar global market leaders, driving high-growth businesses, improving turn-arounds and acquisition integration. Led financial organizations from 5 to 200 employees.Areas of expertise:Growth Strategies | Global Leadership | Board Member | Fact-Based Decision Support | Strategic & Financial Planning | Worldwide P&L Management | International Finance | Cost Accounting | Competitive Intelligence | Talent DevelopmentAdditional skills:Internal Financial Controls | Financial & Portfolio Analysis | Tax Planning | International Treasury Functions | Capital Structure & Cash Management | Mergers & Acquisition | Project Management | Investor Relations | New Product Launches | Acquisition Integration

Robert M. Davis is corporate vice president and president of Baxter's Medical Products business. In this position, Davis oversees a range of products used in the delivery of fluids and drugs to patients, and in the treatment of end-stage kidney disease. Davis took on his current role in October 2010. Prior to this role, Davis served as corporate vice president and president of Baxter's Renal business. He served as corporate vice president and chief financial officer from 2006 through May 2010, and as treasurer from 2004 through 2006. Davis joined Baxter as treasurer in November 2004 from Eli Lilly and Company, where he served in numerous positions of increasing responsibility over 14 years. Davis currently serves on the Board of Trustees for Rush University Medical Center and also serves as a member of the Finance Committee. He also is a member of the Board of Directors of AdvaMed.

Douglas C. Bryant became President and Chief Executive Officer on March 1, 2009. Prior to joining Quidel, Mr. Bryant served as Executive Vice President and Chief Operating Officer at Luminex Corporation, managing its Bioscience Group, Luminex Molecular Diagnostics (Toronto), manufacturing, R&D, technical operations, and commercial operations. From 1983 to 2007, he held various worldwide commercial operations positions with Abbott Laboratories including, among others: Vice President of Abbott Vascular for Asia/Japan, Vice President of Abbott Molecular Global Commercial Operations and Vice President of Abbott Diagnostics Global Commercial Operations. Earlier in his career with Abbott, Mr. Bryant was Vice President of Diagnostic Operations in Europe, the Middle East and Africa, and Vice President of Diagnostic Operations Asia Pacific. Mr. Bryant holds a B.A. in Economics from the University of California at Davis.